Limits...
Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.

Iqbal MS, Shaikh G, Chatterjee S, Cocks H, Kovarik J - Case Rep Oncol Med (2014)

Bottom Line: One distinct feature is their resemblance to ductal carcinomas of breast.Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab.We have also reviewed the published literature on the use of trastuzumab in SDCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.

ABSTRACT
Salivary ductal carcinomas (SDCs) are extremely rare and aggressive malignancies, accounting for approximately 6% of all salivary gland malignancies. One distinct feature is their resemblance to ductal carcinomas of breast. A significant percentage of SDCs overexpress Her2 and the use of targeted therapy with trastuzumab can be considered in these patients. We report a rare case of long term disease control with trastuzumab in Her2 positive metastatic parotid ductal carcinoma. Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab. We have also reviewed the published literature on the use of trastuzumab in SDCs.

No MeSH data available.


Related in: MedlinePlus

HER2 immunohistochemistry of cerebellar lesion—the vast majority of the neoplastic cells are positive with strong cytoplasmic membrane staining.
© Copyright Policy
Related In: Results  -  Collection

License
getmorefigures.php?uid=PMC4127246&req=5

fig2: HER2 immunohistochemistry of cerebellar lesion—the vast majority of the neoplastic cells are positive with strong cytoplasmic membrane staining.

Mentions: A further 8 months later, he presented with increased lethargy, vomiting, weakness, and incoordination. An MRI of spine showed extensive bony metastases but no sign of further cord compression. A CT head however showed a solitary left cerebellar mass obstructing the cerebral aqueduct. He underwent a posterior fossa craniotomy and excision of the metastasis. The histology confirmed metastatic parotid gland ductal carcinoma and Her2 was overexpressed (Figures 1 and 2). Postoperatively he received 20 Gy in 5 fractions of adjuvant radiotherapy to the whole brain. Trastuzumab was discontinued at the time of craniotomy.


Maintenance therapy with trastuzumab in her2 positive metastatic parotid ductal adenocarcinoma.

Iqbal MS, Shaikh G, Chatterjee S, Cocks H, Kovarik J - Case Rep Oncol Med (2014)

HER2 immunohistochemistry of cerebellar lesion—the vast majority of the neoplastic cells are positive with strong cytoplasmic membrane staining.
© Copyright Policy
Related In: Results  -  Collection

License
Show All Figures
getmorefigures.php?uid=PMC4127246&req=5

fig2: HER2 immunohistochemistry of cerebellar lesion—the vast majority of the neoplastic cells are positive with strong cytoplasmic membrane staining.
Mentions: A further 8 months later, he presented with increased lethargy, vomiting, weakness, and incoordination. An MRI of spine showed extensive bony metastases but no sign of further cord compression. A CT head however showed a solitary left cerebellar mass obstructing the cerebral aqueduct. He underwent a posterior fossa craniotomy and excision of the metastasis. The histology confirmed metastatic parotid gland ductal carcinoma and Her2 was overexpressed (Figures 1 and 2). Postoperatively he received 20 Gy in 5 fractions of adjuvant radiotherapy to the whole brain. Trastuzumab was discontinued at the time of craniotomy.

Bottom Line: One distinct feature is their resemblance to ductal carcinomas of breast.Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab.We have also reviewed the published literature on the use of trastuzumab in SDCs.

View Article: PubMed Central - PubMed

Affiliation: Department of Clinical Oncology, Northern Centre for Cancer Care, Freeman Hospital, Newcastle upon Tyne NE7 7DN, UK.

ABSTRACT
Salivary ductal carcinomas (SDCs) are extremely rare and aggressive malignancies, accounting for approximately 6% of all salivary gland malignancies. One distinct feature is their resemblance to ductal carcinomas of breast. A significant percentage of SDCs overexpress Her2 and the use of targeted therapy with trastuzumab can be considered in these patients. We report a rare case of long term disease control with trastuzumab in Her2 positive metastatic parotid ductal carcinoma. Our case also highlights that isolated brain metastasis should be managed aggressively to allow optimal local control when systemic disease is under remission with trastuzumab. We have also reviewed the published literature on the use of trastuzumab in SDCs.

No MeSH data available.


Related in: MedlinePlus